Shilpa Medicare Expands Europe Tie-Up with Orion Pharma


    By Dalal Street Investment Journal (DSIJ)

    Summary :

     

    Shilpa Medicare share prices rose 5% after its subsidiary, Shilpa Biologicals, signed a co-development and exclusive supply agreement with Finland's Orion Corporation for a nivolumab biosimilar in the European market.

    Shilpa

    Shilpa Medicare share prices were trading at ₹601.45 as of 10:45 AM on June 30, 2026, up 5% for the day. The stock touched an intraday high of ₹605.50 and a low of ₹576. Trading volume stood at 1.05 lakh shares compared with the 30-day average volume of 1.48 lakh shares.

    The gain came on the back of an announcement made by the company that its wholly owned subsidiary, Shilpa Biologicals Private Limited (SBPL), has entered into a co-development and supply agreement with Orion Corporation, a globally recognised pharmaceutical company headquartered in Finland.

    Details of the Agreement

    Under the agreement, Shilpa Biologicals will co-develop, manufacture, and exclusively supply an intravenous nivolumab biosimilar, which references one of the world's most widely used cancer immunotherapies. Nivolumab is a PD-1 immunotherapy drug used in the treatment of cancers such as melanoma and lung cancer, and it recorded sales of approximately USD 4.1 billion in Europe in 2025, according to IQVIA and IMS data.

    Shilpa Medicare Ltd

    Trade

    599.8526.25 (4.57 %)

    Updated - 30 June 2026
    615.00day high
    DAY HIGH
    576.00day low
    DAY LOW
    1876264
    VOLUME (BSE)

    Orion Corporation would have the exclusive rights to register, market, distribute and sell the biosimilar in Europe. Shilpa Biologicals would be the company responsible for the development of the product and the exclusive long-term manufacturer and supplier for Europe by manufacturing the biosimilar using the biologics plant located at Dharwad, India.

    Business Impact of the Agreement 

    Shilpa Medicare stated that it is entitled to receive certain development and regulatory milestone payments from Orion under the agreement, in addition to ongoing supply revenue over the life of the partnership. While specific financial terms have not been disclosed, the structure indicates a long-term revenue stream tied to both development milestones and commercial supply once the product reaches the market.

    The agreement builds on an earlier collaboration between the two companies, under which Shilpa had supplied its Recombinant Human Albumin product to Orion for the European market. This nivolumab deal represents an expansion of that existing relationship rather than a standalone new partnership.

    Management Commentary of Shilpa Medicare

    Commenting on the development, Vishnukant Bhutada, Managing Director of Shilpa Medicare, said extending the partnership with Orion in immuno-oncology is a defining moment for Shilpa Biologicals, reflecting the trust placed in the company's quality, science, and ability to deliver complex biologics at scale. Satu Ahomäki, EVP Generics and Consumer Health at Orion Pharma, said the agreement is a step forward in efforts to expand and strengthen operations in the hospital segment in continental Europe.

    About Shilpa Medicare & Orion Corporation

    Shilpa Medicare Limited, headquartered in India, is a diversified pharmaceutical and biotechnology company engaged in the development and manufacture of complex generics, biologics, and active pharmaceutical ingredients. Through its subsidiary Shilpa Biologicals, the company operates a fully integrated biologics platform spanning development, scale-up, and commercial manufacturing at its EU-GMP certified facility in Dharwad, India.

    Orion Corporation is a Nordic pharmaceutical company with over a hundred years of operating history. The company develops, manufactures, and markets human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, with core therapy areas spanning oncology and pain management, alongside proprietary and generic medicines and consumer health products. In 2025, Orion reported net sales of EUR 1,890 million and employs approximately 4,000 professionals worldwide.

    Summary

    The agreement gives Shilpa Medicare a presence in the European nivolumab biosimilar market through its long-term manufacturing and supply role, while Orion gains exclusive commercial rights across the region as the originator product approaches loss of exclusivity in Europe. The companies have positioned the partnership as an effort to widen patient access to immuno-oncology treatment while easing the cost burden on European healthcare systems.

    Source: Dalal Street Investment Journal

     

    About the Author

    SEBI Registered Research Analyst (INH000006396).


    Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise. 

    Published Date : 30 Jun 2026

    Disclaimer :

    Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.


    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    9 lakh+ Users

    icon-with-text

    4.9 App Rating

    icon-with-text

    4 Languages

    icon-with-text

    ₹7,300 Cr+ MTF Book

    icon-with-text